187 related articles for article (PubMed ID: 28384261)
21. Intralesional meglumine antimoniate for treatment of cutaneous leishmaniasis patients with contraindication to systemic therapy from Rio de Janeiro (2000 to 2006).
Vasconcellos Ede C; Pimentel MI; Schubach Ade O; de Oliveira Rde V; Azeredo-Coutinho RB; Silva Fda C; Salgueiro Mde M; Moreira JS; Madeira Mde F; Baptista C; Valete-Rosalino CM
Am J Trop Med Hyg; 2012 Aug; 87(2):257-60. PubMed ID: 22855754
[TBL] [Abstract][Full Text] [Related]
22. Comparison of the effectiveness of two topical paromomycin treatments versus meglumine antimoniate for New World cutaneous leishmaniasis.
Armijos RX; Weigel MM; Calvopiña M; Mancheno M; Rodriguez R
Acta Trop; 2004 Jul; 91(2):153-60. PubMed ID: 15234664
[TBL] [Abstract][Full Text] [Related]
23. Comparative study of the efficacy of oral ketoconazole with intra-lesional meglumine antimoniate (Glucantime) for the treatment of cutaneous leishmaniasis.
Salmanpour R; Handjani F; Nouhpisheh MK
J Dermatolog Treat; 2001 Sep; 12(3):159-62. PubMed ID: 12243707
[TBL] [Abstract][Full Text] [Related]
24. Treatment of cutaneous leishmaniasis with a combination of allopurinol and low-dose meglumine antimoniate.
Momeni AZ; Reiszadae MR; Aminjavaheri M
Int J Dermatol; 2002 Jul; 41(7):441-3. PubMed ID: 12121563
[TBL] [Abstract][Full Text] [Related]
25. Comparison of intralesionally injected zinc sulfate with meglumine antimoniate in the treatment of acute cutaneous leishmaniasis.
Iraji F; Vali A; Asilian A; Shahtalebi MA; Momeni AZ
Dermatology; 2004; 209(1):46-9. PubMed ID: 15237267
[TBL] [Abstract][Full Text] [Related]
26. Dressings combined with injection of meglumine antimoniate in the treatment of cutaneous leishmaniasis: a randomized controlled clinical trial.
Khatami A; Talaee R; Rahshenas M; Khamesipour A; Mehryan P; Tehrani S; Dowlati Y; Firooz A
PLoS One; 2013; 8(6):e66123. PubMed ID: 23826087
[TBL] [Abstract][Full Text] [Related]
27. Intralesional treatment of cutaneous leishmaniasis with meglumine antimoniate.
Aste N; Pau M; Ferreli C; Biggio P
Br J Dermatol; 1998 Feb; 138(2):370-1. PubMed ID: 9602904
[No Abstract] [Full Text] [Related]
28. Weekly vs. fortnightly intralesional meglumine antimoniate in cutaneous leishmaniasis.
Mujtaba G; Khalid M
Int J Dermatol; 1999 Aug; 38(8):607-9. PubMed ID: 10487452
[No Abstract] [Full Text] [Related]
29. Treatment of imported New World cutaneous leishmaniasis in Germany.
Harms G; Scherbaum H; Reiter-Owona I; Stich A; Richter J
Int J Dermatol; 2011 Nov; 50(11):1336-1342. PubMed ID: 22004484
[TBL] [Abstract][Full Text] [Related]
30. Randomized controlled clinical trial to access efficacy and safety of miltefosine in the treatment of cutaneous leishmaniasis Caused by Leishmania (Viannia) guyanensis in Manaus, Brazil.
Chrusciak-Talhari A; Dietze R; Chrusciak Talhari C; da Silva RM; Gadelha Yamashita EP; de Oliveira Penna G; Lima Machado PR; Talhari S
Am J Trop Med Hyg; 2011 Feb; 84(2):255-60. PubMed ID: 21292895
[TBL] [Abstract][Full Text] [Related]
31. Resolution of cutaneous leishmaniasis after acute eczema due to intralesional meglumine antimoniate.
Ferreira e Vasconcellos Ede C; Pimentel MI; Valete-Rosalino CM; Madeira Mde F; Schubach Ade O
Rev Inst Med Trop Sao Paulo; 2014; 56(4):361-2. PubMed ID: 25076440
[TBL] [Abstract][Full Text] [Related]
32. A double-blind randomized clinical trial of a topical herbal extract (Z-HE) vs. systemic meglumine antimoniate for the treatment of cutaneous leishmaniasis in Iran.
Zerehsaz F; Salmanpour R; Handjani F; Ardehali S; Panjehshahin MR; Tabei SZ; Tabatabaee HR
Int J Dermatol; 1999 Aug; 38(8):610-2. PubMed ID: 10487453
[No Abstract] [Full Text] [Related]
33. Standardization of intralesional meglumine antimoniate treatment for cutaneous leishmaniasis.
Duque MC; Vasconcellos ÉC; Pimentel MI; Lyra MR; Pacheco SJ; Marzochi MC; Rosalino CM; Schubach AO
Rev Soc Bras Med Trop; 2016; 49(6):774-776. PubMed ID: 28001228
[TBL] [Abstract][Full Text] [Related]
34. Treatment of cutaneous leishmaniasis with either topical paromomycin or intralesional meglumine antimoniate.
Faghihi G; Tavakoli-kia R
Clin Exp Dermatol; 2003 Jan; 28(1):13-6. PubMed ID: 12558620
[TBL] [Abstract][Full Text] [Related]
35. Miltefosine in the treatment of cutaneous leishmaniasis caused by Leishmania braziliensis in Brazil: a randomized and controlled trial.
Machado PR; Ampuero J; Guimarães LH; Villasboas L; Rocha AT; Schriefer A; Sousa RS; Talhari A; Penna G; Carvalho EM
PLoS Negl Trop Dis; 2010 Dec; 4(12):e912. PubMed ID: 21200420
[TBL] [Abstract][Full Text] [Related]
36. In vivo antileishmanial efficacy of miltefosine against Leishmania (Leishmania) amazonensis.
García Bustos MF; Barrio A; Prieto GG; de Raspi EM; Cimino RO; Cardozo RM; Parada LA; Yeo M; Soto J; Uncos DA; Parodi C; Basombrío MA
J Parasitol; 2014 Dec; 100(6):840-7. PubMed ID: 25014108
[TBL] [Abstract][Full Text] [Related]
37. Ex vivo host and parasite response to antileishmanial drugs and immunomodulators.
Gonzalez-Fajardo L; Fernández OL; McMahon-Pratt D; Saravia NG
PLoS Negl Trop Dis; 2015 May; 9(5):e0003820. PubMed ID: 26024228
[TBL] [Abstract][Full Text] [Related]
38. Overcoming the Challenge; In Vivo Efficacy of Miltefosine for Chronic Cutaneous Leishmaniasis.
Tunalı V; Harman M; Çavuş İ; Gündüz C; Özbilgin A; Turgay N
Acta Parasitol; 2021 Jun; 66(2):354-360. PubMed ID: 32996014
[TBL] [Abstract][Full Text] [Related]
39. Miltefosine for new world cutaneous leishmaniasis.
Soto J; Arana BA; Toledo J; Rizzo N; Vega JC; Diaz A; Luz M; Gutierrez P; Arboleda M; Berman JD; Junge K; Engel J; Sindermann H
Clin Infect Dis; 2004 May; 38(9):1266-72. PubMed ID: 15127339
[TBL] [Abstract][Full Text] [Related]
40. Cutaneous leishmaniasis in Switzerland: first experience with species-specific treatment.
Mosimann V; Neumayr A; Hatz C; Blum JA
Infection; 2013 Dec; 41(6):1177-82. PubMed ID: 23835701
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]